$130.52
+0.21%ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Chief Executive Officer & Chairman of the Board
Compensation
$1,954,750
Chief Financial Officer & Treasurer
Compensation
$991,000
Chief Information Officer
Chief Operating Officer
Compensation
$1,042,250
Corporate Vice President, General Counsel, Secretary & Compliance Officer
Compensation
$898,750
President
Compensation
$718,500
Vice President of Human Resources
During the last 12 months, insiders have purchased $343K and sold $1.64M worth of ICUI shares, resulting in $1.29M of net selling activity.
0
0.00
7.0K
882.24K
-882K
-$882K
0
0.00
0
0.00
+0
+$0
0
0.00
5.1K
754.18K
-754K
-$754K
3.0K
342.55K
0
0.00
+343K
+$343K
Jain Vivek
Director, Officer: Chairman And Ceo
$267K
Greenberg David C.
Director
$76K
Woolson Daniel
Officer: President
$722K
Sanzone Virginia Ruth
Officer: Vp, General Counsel
$436K
Greenberg David C.
Director
$298K
Finney Elisha W
Director
$180K
Strong bearish signal with $1.29M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
ICUI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 02, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 03, 2025 | April 03, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 02, 2024 | May 15, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 04, 2023 | April 04, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 04, 2022 | April 04, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 01, 2021 | April 01, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 03, 2020 | April 03, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 05, 2019 | May 15, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 05, 2018 | May 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 10, 2017 | May 09, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.